Human GLP1R Virus-Like Particles

The human glucagon-like peptide-1 receptor (GLP1R) is a class B G protein-coupled receptor (GPCR) that plays a key role in glucose metabolism and insulin secretion. GLP1R is primarily expressed in pancreatic β cells and is activated by its endogenous ligand, glucagon-like peptide-1 (GLP-1), which is released by intestinal L cells in response to nutrient intake. GLP1R activation triggers an intracellular signaling cascade that enhances glucose-dependent insulin secretion, inhibits glucagon release, promotes β-cell proliferation, and inhibits apoptosis. These actions make GLP1R a key therapeutic target for type 2 diabetes mellitus (T2DM) and obesity.

Virus-like particles (VLPs) are nanoscale structures that mimic the structure of viral capsids but lack infectious genetic material, making them safe and highly immunogenic platforms for therapeutic and vaccine applications. GLP1R-targeted VLPs are engineered to display GLP1R ligands or agonists on their surface, enabling targeted delivery to pancreatic β cells or other GLP1R-expressing tissues. These VLPs can encapsulate drugs, nucleic acids, or imaging agents, leveraging their natural tropism and biocompatibility to enable precision medicine. For example, GLP1R VLPs can enhance the stability and bioavailability of GLP-1 analogs, prolong their duration of action, and reduce dosing frequency. Furthermore, their modular design enables them to be combined with other functional moieties, such as immunomodulators or cell-penetrating peptides, to further optimize therapeutic efficacy.